Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 1255b-2 (MIR1255B2) is a human microRNA gene encoding a short, non-coding RNA molecule typically 20-24 nucleotides in length[1]. Like other microRNAs, it is transcribed as a primary transcript, processed by the Drosha and Dicer enzymes into a mature miRNA that is loaded into the RNA-induced silencing complex (RISC), where it guides the complex to target mRNAs via imperfect base pairing, resulting in inhibition of translation or degradation of the mRNA[1]. MIR1255B2 is part of a paralogous cluster along with miR-99a and let-7c, and is implicated in tumor subtypes through differential expression patterns, notably in breast and multiple myeloma molecular subgroups[3][7]. While there is no direct evidence it is currently a defined therapeutic target, its regulatory role in gene expression and presence in pathways relevant to cancer suggest potential research relevance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 1255b-2 (MIR1255B2).